The Alzheimer’s disease drug development landscape

BACKGROUND: Alzheimer’s disease (AD) is a devastating neurodegenerative disease leading to dementia. The field has made significant progress over the last 15 years. AD diagnosis has shifted from syndromal, based on signs and symptoms, to a biomarker construct based on the pathological hallmarks of t...

Descripción completa

Detalles Bibliográficos
Autores principales: van Bokhoven, Pieter, de Wilde, Arno, Vermunt, Lisa, Leferink, Prisca S., Heetveld, Sasja, Cummings, Jeffrey, Scheltens, Philip, Vijverberg, Everard G. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582156/
https://www.ncbi.nlm.nih.gov/pubmed/34763720
http://dx.doi.org/10.1186/s13195-021-00927-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582156/
https://www.ncbi.nlm.nih.gov/pubmed/34763720
http://dx.doi.org/10.1186/s13195-021-00927-z

Ejemplares similares